ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial

Study limitation reported by the research below: “The 'practice changing' impact flag is applied in the negative direction — this trial argues against a new approach rather than establishing one, which is an important distinction for clinical interpretation.”

Papers